Safety and Efficacy of Klotho and Follistatin Gene Therapy

Last updated: January 6, 2026
Sponsor: Minicircle
Overall Status: Active - Recruiting

Phase

1

Condition

N/A

Treatment

Follistatin and klotho gene therapy

Clinical Study ID

NCT07285629
GIFIRB202507313
  • Ages 50-80
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of this study is to investigate the safety and efficacy of a combination klotho and follistatin gene therapy, delivered via a nonviral plasmid in healthy adult volunteers. Additionally, this study seeks to understand the cognitive and health benefits of this gene therapy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adults aged 50 to 80 years

  • General good health

  • Willing to comply with all study-related procedures and visits

  • Participant is open to morphological change

  • If female, participant agrees to maintain contraception

  • If female, participant agrees to take a pregnancy test

  • If female, participant agrees to a pregnancy waiver

Exclusion

Exclusion Criteria:

  • Currently enrolled in another clinical trial

  • History of cancer, autoimmune disease, or chronic kidney/liver disease

  • Use of immunosuppressive therapy

  • Pregnant or breastfeeding

  • Women of childbearing potential who are unwilling or unable to use effectivecontraception for the duration of the study.

  • Regular use of NMDA (N-methyl-D-aspartate) antagonists (i.e., memantine, ketamine,etc.)

  • Regular use of antiplatelet medications (i.e., aspirin)

  • Any medical or psychiatric condition that could interfere with participation or posesafety concerns

  • Unwilling or unable to provide informed consent

Study Design

Total Participants: 30
Treatment Group(s): 1
Primary Treatment: Follistatin and klotho gene therapy
Phase: 1
Study Start date:
December 16, 2025
Estimated Completion Date:
June 30, 2026

Study Description

Healthy participants will take part in cognitive and health testing before and after administration of plasmid-delivered nonviral klotho and follistatin gene therapy. The method of administration will be subcutaneous injection into abdominal fat deposits. Klotho and follistatin plasmid gene therapy have the potential to improve physical function, cognitive function, kidney function, body composition, epigenetic age, and subjective well being.

Note that the investigational product will be administered at a site outside of the U.S. which is not under FDA jurisdiction, and only non-treatment pre/post outcome assessments (e.g., cognitive assessments or blood sample collection) occur at the U.S. site.

Connect with a study center

  • Global Alliance of Regenerative Medicine (GARM) Clinic

    Roatán 10792300, Bay Islands 3608814
    Honduras

    Site Not Available

  • Apeiron Center

    Austin 4671654, Texas 4736286 78701
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.